These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16216529)

  • 21. Phenylpropanolamine, stroke and hypertension.
    Kuchel O
    CMAJ; 2001 Mar; 164(5):621. PubMed ID: 11258207
    [No Abstract]   [Full Text] [Related]  

  • 22. An ingredient under fire. Drugmakers are jittery after an FDA panel ruling.
    Noonan D
    Newsweek; 2000 Oct; 136(18):59. PubMed ID: 11185358
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of Ephedra-containing products and risk for hemorrhagic stroke.
    Morgenstern LB; Viscoli CM; Kernan WN; Brass LM; Broderick JP; Feldmann E; Wilterdink JL; Brott T; Horwitz RI
    Neurology; 2003 Jan; 60(1):132-5. PubMed ID: 12525737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A stroke is nothing to sneeze at.
    Rocca PV
    Del Med J; 2000 Nov; 72(11):495-6. PubMed ID: 11125666
    [No Abstract]   [Full Text] [Related]  

  • 25. Underreporting of hemorrhagic stroke associated with phenylpropanolamine.
    La Grenade L; Graham DJ; Nourjah P
    JAMA; 2001 Dec; 286(24):3081. PubMed ID: 11754672
    [No Abstract]   [Full Text] [Related]  

  • 26. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 30. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. US Senate passes FDA Revitalization Act.
    Guthrie P
    CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
    [No Abstract]   [Full Text] [Related]  

  • 32. Phenylpropanolamine-associated intracranial hemorrhage in an infant.
    Hamilton RS; Sharieff G
    Am J Emerg Med; 2000 May; 18(3):343-5. PubMed ID: 10830700
    [No Abstract]   [Full Text] [Related]  

  • 33. Science and regulation. FDA's approach to regulation of products of nanotechnology.
    Hamburg MA
    Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845
    [No Abstract]   [Full Text] [Related]  

  • 34. By the way, doctor. NOw that pollen season is underway, I need a decongestant. The one I've used for years was taken off the market because it contained PPA. What is PPA, and why is it a problem? What can I use instead?
    Robb-Nicholson C
    Harv Womens Health Watch; 2001 May; 8(9):7-8. PubMed ID: 11424274
    [No Abstract]   [Full Text] [Related]  

  • 35. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).
    Weaver J; Grenade LL; Kwon H; Avigan M
    Dermatol Ther; 2009; 22(3):204-15. PubMed ID: 19453344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New therapeutic agents marketed in 1993.
    Hussar DA
    Pa Med; 1994 May; 97(5):12-7. PubMed ID: 8036027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA: friend or foe?
    Lewis TS
    Med Device Technol; 1996 Nov; 7(9):24-30. PubMed ID: 10163675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
    Lang L
    Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
    [No Abstract]   [Full Text] [Related]  

  • 39. Psychiatric side effects attributed to phenylpropanolamine.
    Lake CR; Masson EB; Quirk RS
    Pharmacopsychiatry; 1988 Jul; 21(4):171-81. PubMed ID: 3060884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Original research: Intravenous ribavirin--review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review.
    Riner A; Chan-Tack KM; Murray JS
    Postgrad Med; 2009 May; 121(3):139-46. PubMed ID: 19491552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.